#1 Clinical Trials Search in Europe

Ly3871801

Clinical trials are studying Ly3871801 in adults with rheumatoid arthritis. These studies are looking at whether it can improve disease activity and help more people reach meaningful treatment responses. The main focus is on efficacy, with placebo used for comparison.

Table of contents

Trial overview

The available trial data describe an adaptive Phase 2a/2b study of Ly3871801 in adults with rheumatoid arthritis.[1] The study was designed to compare Ly3871801 with a placebo, which is an inactive treatment used as a comparison.[1]

This trial is listed as completed and enrolled 332 participants.[1] It was an interventional study, meaning researchers gave a study treatment and then measured the effects.[1]

Who was studied

The study focused on adult participants with rheumatoid arthritis.[1] No other participation rules are provided in the source data, so the exact age limits, background treatments, and other entry criteria are not available here.

  • Adults with rheumatoid arthritis: The main group in this trial, so the results are meant for people living with this long-term joint disease.[1]
  • Placebo comparison: Some participants received a placebo to help show whether any change was due to Ly3871801 rather than chance.[1]

What was measured

The study used different measures in the Phase 2a and Phase 2b parts.[1] These are called primary outcomes, which are the main results researchers plan to look at first.[1]

  • DAS28-hsCRP: In Phase 2a, researchers measured the change from baseline in the Disease Activity Score using high-sensitivity C-reactive protein.[1] This score helps show how active rheumatoid arthritis is, and a lower score usually means less disease activity.
  • ACR50: In Phase 2b, researchers measured the percentage of participants who achieved ACR50.[1] This means a 50% improvement based on standard arthritis criteria.
  • Change from baseline: Baseline means the starting point before treatment, so the study checked whether participants improved over time.[1]

How the study was designed

The title describes the study as adaptive, which means the study design can change based on information collected during the trial.[1] The trial also included both a Phase 2a part and a Phase 2b part, showing that it moved from early testing to a broader check of effect.[1]

Ly3871801 was studied against placebo in an oral form listed in the intervention data.[1] The source data do not give more detail about visit schedules, randomization, or how long participants were followed.

What the trial results mean for patients

For patients, this trial is mainly about whether Ly3871801 can help reduce the signs and symptoms of rheumatoid arthritis better than placebo.[1] The study looked at both a disease activity score and a standard improvement target, so it assessed more than one way of seeing benefit.[1]

Because the trial is completed, the main value of the data is in understanding how Ly3871801 performed in this study population.[1] However, the source data provided here do not include the final numerical results, so only the study design and outcomes can be summarized from this record.

Trial IDPhaseCondition studiedStatusEnrollment
2022-502994-40-00Phase 2Rheumatoid ArthritisCompleted332

FAQ

  • What is being studied in Ly3871801 trials? The trials are studying Ly3871801 in adults with rheumatoid arthritis. They compare it with a placebo to see whether it improves disease activity and treatment response.
  • Who can take part in these trials? The study is for adult participants with rheumatoid arthritis. Other details about who can join are not provided in the trial data.
  • What phase is the Ly3871801 study? This is a Phase 2 study. It includes both Phase 2a and Phase 2b parts, which means it is looking at early signs of benefit and further testing of effectiveness.
  • What results are the researchers measuring? In Phase 2a, they measure change in DAS28-hsCRP, a score that shows how active the arthritis is. In Phase 2b, they measure how many participants achieve ACR50, which means a 50% improvement based on standard arthritis criteria.
  • How many people were enrolled? The trial enrolled 332 participants. This gives the study a moderate size for testing results in adults with rheumatoid arthritis.

Ongoing Clinical Trials on Ly3871801

  • Study of LY3871801 for Adults with Moderate to Severe Rheumatoid Arthritis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Hungary Poland Slovakia

Glossary

  • Rheumatoid arthritis: A long-term disease where the immune system attacks the joints, causing pain, swelling, and stiffness.
  • Adult participants: People who are 18 years old or older and are taking part in the study.
  • Phase 2: A stage of clinical research that checks whether a treatment seems to work and continues to watch safety.
  • Phase 2a: The first part of a Phase 2 study, often used to look for early signs that a treatment may help.
  • Phase 2b: The later part of a Phase 2 study, used to test how well a treatment works in a larger group.
  • Placebo: An inactive treatment that looks like the study drug but does not contain the active study medicine.
  • Disease Activity Score – high-sensitivity C-reactive protein (DAS28-hsCRP): A score used to measure how active rheumatoid arthritis is. Lower scores usually mean less disease activity.
  • ACR50: A standard measure in rheumatoid arthritis trials meaning a 50% improvement in symptoms and signs of the disease.
  • Efficacy: How well a treatment works in a clinical study.
  • Interventional study: A study where researchers give a treatment and then measure its effects.

References

  1. https://clinicaltrials.gov/study/2022-502994-40-00